Tatiana M. Ostroumova

Tatiana M. Ostroumova

Auto-generated profile, based on publicly available information

Tatiana M. Ostroumova

Russian Medical Academy of Continuous Professional Education; Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
VPVladimir Parfenov
Vladimir Parfenov
OOOlga D Ostroumova
Olga D Ostroumova
TOTatiana M Ostroumova
Tatiana M Ostroumova
AKAlexey I Kochetkov
Alexey I Kochetkov
VFVictoria Fateeva
Victoria Fateeva
OEOleg Epstein
Oleg Epstein
Vascular cognitive impairment (VCI) and vascular dementia are the most common forms of cognitive disorder associated with cerebrovascular disease and related to increased morbidity and mortality among the older population. Growing evidence suggests the contribution of blood-pressure variability, cardiac arrhythmia, hyperactivation of the renin–angiotensin–aldosterone system, endothelial dysfunction, vascular remodeling and stiffness, different angiopathies, neural tissue homeostasis, and systemic metabolic disorders to the pathophysiology of VCI. In this review, we focus on factors contributing to cerebrovascular disease, neurovascular unit alterations, and novel approaches to cognitive improvement in patients with cognitive decline. One of the important factors associated with the neuronal causes of VCI is the S100B protein, which can affect the expression of cytokines in the brain, support homeostasis, and regulate processes of differentiation, repair, and apoptosis of the nervous tissue. Since the pathological basis of VCI is complex and diverse, treatment affecting the mechanisms of cognitive disorders should be developed. The prospective role of a novel complex drug consisting of released–active antibodies to S100 and to endothelial NO synthase in VCI treatment is highlighted.

15 March 2021 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
OOOlga D. Ostroumova
Olga D. Ostroumova
VPVladimir Parfenov
Vladimir Parfenov
TOTatiana M. Ostroumova
Tatiana M. Ostroumova
NYNikolay N. Yakhno
Nikolay N. Yakhno
ICIrina E. Chazova
Irina E. Chazova
ШВШих Евгения Валерьевна
Ших Евгения Валерьевна
Arterial hypertension (AH) is the major modifiable risk factor for cognitive impairment (CI), including dementia, CI in cerebrovascular and neurodegenerative diseases, including Alzheimers disease. By 2050, the number of people with dementia will approximately 3 times increase due to the aging population and limited opportunities for drug prevention and treatment of severe CI. In connection with the above, it seems necessary to create an expert consensus, which would summarize the evidence-based medicine data available to date on the effect of antihypertensive therapy (AHT) on cognitive function (CF). In the expert consensus, the data of prospective randomized clinical trials, observational and population studies, meta-analyzes on the effect of AHT on the risk of dementia and CI progression, including certain CF, were summarized and analyzed. The consensus considers the effect of antihypertensive drugs (AHD) on various cognitive domains. Literature data give evidence that AHT reduces the risk for dementia, including vascular dementia, reduces the risk of for dementia in Alzheimers disease, as well as reduces the risk and can prevent the progression of non-dementia CI. The effect of AHT on various CF has been little studied. Most meta-analyzes did not reveal the benefits of any class of AHD; however, one study demonstrated the advantage of angiotensin receptor blockers, while another study diuretics. The consensus emphasizes that, given the high incidence of AH in the general population, AHT may be one of the most effective ways to prevent CI or delay CI progression. The effect of different classes of AHD on CF requires further study. It is necessary to conduct a larger number of well-designed randomized clinical trials that would assess the state of executive functions in patients with AH.

1 January 2018 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
VPVladimir Parfenov
Vladimir Parfenov
TOT M Ostroumova
T M Ostroumova
OOO D Ostroumova
O D Ostroumova
EPE E Pavleyva
E E Pavleyva
Aim. To evaluate the presence and the severity of the complaints (headache, dizziness, memory loss, concentration of attention, sleep disturbances, decreased mood, increased anxiety), the state of cognitive functions, emotional status and quality of night sleep in treatment-nanve middle-aged patients with mild to moderate EAH compared to healthy volunteers of the same age. Materials and methods. 103 treatment-nanve patients with EAH aged 40-59 years at the enrollment, who met the inclusion/exclusion criteria and provided written informed consent (46 men, mean age 53.6 +/- 0.8 years) and 50 healthy volunteers (17 men, mean age 51.5 +/- 1.0 years) with normal blood pressure (BP) level - control group - were enrolled to the study. Mean EAH duration was 2.9 +/- 5.7 years. Cognitive assessment included Montreal cognitive assessment, 10-words learning task, verbal fluency test, TMT, Stroop color and word test. Anxiety and depression were evaluated via Hamilton rating scales (HARS and HORS). 24-hours ambulatory BP monitoring (ABPM) was performed according to European guidelines. Results. 70% of patients with EAH complained of memory disturbance, 68% - lack of attention, 22% - sleep disturbances, 12% - dizziness, 9% - headache. It took statistically significant more time for patients with EAH to perform on TMT B (p<0.05), they had significantly higher TMT B - TMT A difference score (p<0.01) and lower mean MoCA score (p<0.05). Patients with EAH had significantly higher mean score in Hamilton anxiety (2.1 +/- 3.7) and depression (1.1 +/- 2.4) rating scales compared to controls (0.3 +/- 0.9 points, p<0.01 and 0.1 +/- 0.5 points, p<0.001, respectively). Patients with EAH who complained of sleep disturbances had low sleep quality (8.7 +/- 2.8 points). Among patients with EAH who complained about headaches 66.6% had episodic migraine and chronic tension type headache (33.4%). Those patients had a substantial impact of headache on life and daily living according to I IIT-6 (mean score - 57.5 +/- 6.1). Only 2 patients out of 12 with complains about dizziness had benign paroxysmal positional vertigo and Milnimre's disease. Conclusion. Complaints about memory dysfunction, lack of attention, sleep disturbances, less common dizziness and headaches, are most typical in patients with EAH on the early stages of the disease. They differ from healthy volunteers of the same age by having cogni Live impairment and higher anxiety and depression scores. Patients with EAH who complained about sleep disturbances had low sleep quality. Headache in patients with EAH was due to episodic migraine and tension type headache which had a negative impact on life and daily living.

16 March 2021 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
DSDmitry Sychev
Dmitry Sychev
OOO. D. Ostroumova
O. D. Ostroumova
APA. P. Pereverzev
A. P. Pereverzev
AKA. I. Kochetkov
A. I. Kochetkov
TOT. M. Ostroumova
T. M. Ostroumova
EEE. Yu. Ebzeeva
E. Yu. Ebzeeva
Some patients are more likely to have drug-induced diseases due to a number of risk factors, such as older age. The aim of the study was to analyse the effect of older age on pharmacokinetics and pharmacodynamics of medicines and the risk of developing drug-induced diseases. The analysis of scientific literature demonstrated that changes in the functions of body organs and systems caused by natural aging processes may potentially affect pharmacokinetics and pharmacodynamics of medicines and increase the risk of adverse drug reactions. For instance, older people have a decreased cardiac output both at rest and during exercise, weight loss, loss of elasticity of elastic vessels, a reduced number of functioning nephrons, poorer renal filtration capacity, decreased liver volume, a reduced number of functioning hepatocytes, decreased hepatic blood flow. These changes directly affect absorption, metabolism, distribution, and excretion of medicines, which in turn can affect their safety profiles. Consideration of age-related changes in the functions of body organs and systems, regular monitoring of the efficacy and safety of the prescribed medicine, changing the dosage regimen, and revision of the treatment sheet by healthcare professionals will help optimize pharmacotherapy and reduce the risk of adverse reactions and drug-induced diseases in older patients.

5 June 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MPMikhail Poluektov
Mikhail Poluektov
EAE.S. Akarachkova
E.S. Akarachkova
EDE.V. Dovgan
E.V. Dovgan
OKO.V. Kotova
O.V. Kotova
TDT.YU. Demidova
T.YU. Demidova
TOT.M. Ostroumova
T.M. Ostroumova
Sleep disorders are becoming increasingly important due to the high comorbidity with other diseases and a significant impact on the patient’s quality of life. Insomnia is the most common sleep disorder both in the general population and in patients with multimorbid pathology. Its prevalence in the general population is 6—15%, while in patients with somatic diseases it increases up to 20—40% and can reach 90% in patients with comorbid mental disorders. Another problem is the development of drug-induced insomnia. Insomnia has negative impact on the prognosis of comorbid diseases, including an increased risk of death, more severe disease, and a worse quality of life. The presence of sleep disorders makes it difficult to effectively treat the underlying disease, so it is extremely important to identify and correct these disorders in the early stages, therefore recommendations for the diagnosis of insomnia in polymorbid patients are proposed. Modern methods of treating acute and chronic insomnia and features of insomnia treatment in polymorbid patients are also discussed.

6 May 2019 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
TOT. M. Ostroumova
T. M. Ostroumova
VPVladimir Parfenov
Vladimir Parfenov
OOO. D. Ostroumova
O. D. Ostroumova
Cognitive impairment in patients with arterial hypertension: a relationship with the level and daily blood pressure profile and pathogenetic mechanisms